Raymond James Financial Services Advisors’s Ocular Therapeutix OCUL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $841K | Buy |
96,644
+23,893
| +33% | +$208K | ﹤0.01% | 2273 |
|
|
2024
Q2 | $498K | Buy |
72,751
+18,567
| +34% | +$127K | ﹤0.01% | 2538 |
|
|
2024
Q1 | $493K | Sell |
54,184
-7,856
| -13% | -$71.5K | ﹤0.01% | 2524 |
|
|
2023
Q4 | $277K | Sell |
62,040
-12,361
| -17% | -$55.1K | ﹤0.01% | 2786 |
|
|
2023
Q3 | $234K | Buy |
74,401
+23,637
| +47% | +$74.2K | ﹤0.01% | 2825 |
|
|
2023
Q2 | $262K | Buy |
50,764
+36,009
| +244% | +$186K | ﹤0.01% | 2748 |
|
|
2023
Q1 | $77.8K | Buy |
14,755
+1,700
| +13% | +$8.96K | ﹤0.01% | 3073 |
|
|
2022
Q4 | $36.7K | Sell |
13,055
-21,818
| -63% | -$61.3K | ﹤0.01% | 3098 |
|
|
2022
Q3 | $145K | Buy |
34,873
+4,045
| +13% | +$16.8K | ﹤0.01% | 2920 |
|
|
2022
Q2 | $124K | Buy |
30,828
+9,244
| +43% | +$37.2K | ﹤0.01% | 2965 |
|
|
2022
Q1 | $107K | Sell |
21,584
-45,218
| -68% | -$224K | ﹤0.01% | 3083 |
|
|
2021
Q4 | $466K | Buy |
66,802
+43,073
| +182% | +$300K | ﹤0.01% | 2414 |
|
|
2021
Q3 | $237K | Sell |
23,729
-1,864
| -7% | -$18.6K | ﹤0.01% | 2849 |
|
|
2021
Q2 | $363K | Sell |
25,593
-406
| -2% | -$5.76K | ﹤0.01% | 2589 |
|
|
2021
Q1 | $427K | Buy |
25,999
+1,109
| +4% | +$18.2K | ﹤0.01% | 2395 |
|
|
2020
Q4 | $515K | Buy |
24,890
+3,876
| +18% | +$80.2K | ﹤0.01% | 2125 |
|
|
2020
Q3 | $160K | Sell |
21,014
-28,605
| -58% | -$218K | ﹤0.01% | 2587 |
|
|
2020
Q2 | $413K | Buy |
49,619
+34,143
| +221% | +$284K | ﹤0.01% | 2026 |
|
|
2020
Q1 | $77K | Buy |
+15,476
| New | +$77K | ﹤0.01% | 2261 |
|